2025年3月3日 · At Syndax, we are advancing the next generation of targeted treatments with the goal of realizing a future in which people with cancer live longer and better than ever before. We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft ...

Syndax anticipates submitting a supplemental NDA (sNDA) based on this positive data from the pivotal AUGMENT-101 trial of revumenib in adults and pediatric patients with NPM1m AML in the first half of 2025. You can learn more HERE.

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in …

Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 ...

2024年11月12日 · Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor.

2025年2月25日 · Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.

2024年11月15日 · The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares...

2024年11月12日 · Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the ...